We conducted a randomized, open-label trial in 42 French hospitals to compare the clinical and bacteriologic efficacy of combination therapy with clarithromycin/clofazimine (Clm/Clof) with that of combination therapy with clarithromycin/rifabutin/ethambutol (Clm/Rib/Eth) as treatment for Mycobacterium avium bacteremia. One hundred forty-four human immunodeficiency virus -seropositive patients older than 18 years of age who had CD4 lymphocyte counts of õ100/mm 3 and a blood culture positive for M. avium were enrolled in the study. The main measures of outcome were blood cultures, abatement of clinical symptoms (fever), and survival. Treatment success (defined as patient living, either no fever or a reduction of §1ЊC in initial body temperature, and a blood culture negative for M. avium) was similar in both treatment groups at months 2 and 6. However, following initial resolution of infection, relapse of M. avium bacteremia occurred in more patients in the Clm/Clof group than in the Clm/Rib/Eth group (22 vs. six, respectively; P õ .001); these relapses were accompanied by emergence of strains resistant to clarithromycin in 21 and two patients, respectively. In conclusion, combination therapy with Clm/Rib/Eth prevented relapse of mycobacterial disease and, compared with combination therapy with Clm/Clof, was associated with a significant decrease in the emergence of resistant M. avium strains in HIV-infected patients treated for at least 28 weeks.
studies. The safety and tolerability of each of these combination
Patients were evaluated clinically on treatment days 0 (baseline), 14, and 28 and every 4 weeks thereafter. At each evalua-regimens were also assessed. tion, the following parameters were recorded: weight, morning temperature, incidence of diarrhea and sweats, and Karnofsky Patients and Methods score. A hearing test, eye examination, and assessment of color vision were performed at study entry, at months 2, 6, and 9, Patients or if the patient reported any disturbance in hearing or vision. At each visit, laboratory examinations, including a complete Patients eligible for inclusion in the study met the following blood cell count, blood chemistry analysis, and blood culture criteria: age of older than 18 years, serological test positive for for M. avium, were performed. Treatment safety was assessed HIV and a CD4 lymphocyte count of õ100/mm 3 , at least one by physical examination, vital signs, and the possible occurblood culture positive for M. avium in the 4 weeks before rence of adverse events or laboratory abnormalities and their inclusion in the study, and no active treatment with clarithroseverity, duration, and relationship to the study drugs. In the mycin or azithromycin for M. avium infection for at least 1 event of any serious adverse effect, treatment was to be disconweek before study inclusion. Treatment with study medication tinued, and the study coordinator was notified. Clarithromycin was initiated on the basis of a positive culture, even if dosages were reduced by one-half during the first 8 weeks of M. avium had not yet been definitively identified as the caustreatment if gastrointestinal intolerance or a threefold elevation ative pathogen. Patients for whom rifabutin prophylaxis had in the baseline aminotransferase values occurred. failed were also eligible for study inclusion, since previous studies have reported no increase in the MICs for M. avium strains isolated from such patients [10] .
Microbiological Analyses
Persons with a history of allergy to macrolides or rifamycins Analysis of blood cultures. A quantitative analysis of culand those with aminotransferase levels of greater than five tures of 10-mL blood specimens (stored in Isolator tubes; Dutimes the upper limit of normal or serum creatinine levels of Pont de Nemours, Carter-Wallace, New York) obtained from greater than one and one-half times the upper limit of normal each patient at day 0 was performed. All samples were taken were not eligible for enrollment in the study. Pregnant females, from patients before the administration of any antimycobactepersons with hearing impairment, and patients for whom clarial treatment and processed according to the instructions of rithromycin prophylaxis for M. avium infection had failed were the manufacturer. Determination of cfu was done as follows. also not included.
A 0.1-mL aliquot of the pellet was diluted in 0.9 mL of distilled Written informed consent was obtained from each patient water and distributed equally into four tubes with Löwensteinbefore inclusion in the study. The study protocol was approved Jensen medium. The remainder of the sample was distributed by the consultative Committee for the Protection of Persons without dilution into six to eight tubes with Löwenstein-Jensen that is affiliated with biomedical research at Centre Hospitalier medium. All tubes were incubated at 37ЊC and examined Universitaire (Nancy, France) and by the National Information weekly for growth; if growth was present, the colonies were and Freedom Commission and the administration of each of counted. A culture was considered negative if after 6 months the participating hospitals.
of incubation there was no growth. If the laboratory of a participating hospital routinely used the radiometric method (BAC-TEC System, Becton Dickinson, Sparks, MD), blood samples
Study Design
were sent in an Isolator tube to the Mycobacterial Unit of Institut Pasteur (Paris; reference laboratory for this study). This prospective, open-label, randomized, multicenter study was designed to include a total of 150 patients over a period After the baseline assessment, bacteriologic follow-up analyses were performed by either of the two methods mentioned of 18 months. At the time of study entry, patients were randomized to one of two treatment groups. Patients in the Clm/Clof above (i.e., the DuPont method [either locally or at Institut Pasteur] or the Becton Dickinson method, respectively) ac-group received 2 g of clarithromycin/d (divided in two daily doses) and 200 mg of clofazimine/d for 8 weeks followed by cording to the preference of the participating hospital. Identification of strains of M. avium. The identity of iso-1 g of clarithromycin/d (in two daily doses) and 100 mg of clofazimine/d for at least 18 weeks. Patients in the Clm/Rib/Eth lated strains of M. avium was verified by PCR amplification of the DT6 sequence according to the method described by group received clarithromycin according to the same dosage schedule as in the Clm/Clof group, 450 mg of rifabutin/d, Thierry and colleagues [11] . The study was initiated in January 1994. In June 1995, the scientific committee recommended premature interruption of culture specimens obtained on day 0 and during evaluations at 2 months and thereafter, MICs of each of the four study the study following notification by the independent surveillance committee of the results of the intermediate analysis. This antibacterials were determined by using the Becton Dickinson method. Strains were cultivated on Middlebrook 7H9 medium analysis revealed statistically significant differences between the two treatment groups with regard to the number of relapses before being inoculated in BACTEC 12B bottles until a growth index of 999 was obtained. The culture was then diluted to and the emergence of strains resistant to clarithromycin as well as a tendency toward a difference in patient survival after 6 1:100 and inoculated into a control bottle and also into bottles containing each of the study drugs. A 1:10,000 dilution of the months of treatment. We present the results of the analysis of data collected up to 30 June 1995, the date the study was initial cultures was also prepared in a BACTEC 12B bottle as a control. For MIC testing, twofold concentrations of the various discontinued. antibacterials were prepared in the following ranges: rifabutin, 0.06 -8 mg/L; clarithromycin, 1 -128 mg/L; ethambutol, 0.25 -Study Populations 32 mg/L; and clofazimine, 0.03 -4 mg/L. Growth was determined by daily radiometric measurement of the quantity of CO 2 From January 1994 to June 1995, 144 HIV-seropositive patients were enrolled in the study at 42 hospitals in France. released by using the automatic BACTEC 460TB analyzer. The MIC was considered to be the concentration of antibacterial There were 72 patients in each of the two treatment groups. Ten patients (5 in each treatment group) were excluded from that inhibited 99% of bacterial activity during at least 6 days of culture.
the final analysis for both efficacy and safety because of a negative blood culture in the month preceding study inclusion (6) , because of a blood culture positive for a species of myco-Treatment Outcome bacteria other than M. avium (2), and because of study withdrawal after consent was obtained (2). The success of drug therapy was evaluated for all patients after 2 and 6 months of treatment. At these points, the primary Baseline demographic data are presented in table 1. There were no significant differences between the two treatment determinants of success were as follows: patient living, either no fever or a reduction of §1ЊC in initial body temperature, groups with regard to epidemiological, clinical, or biological characteristics. Thirty-one patients in the Clm/Clof group and a blood culture negative for M. avium. Treatment failure was defined as all other situations. Secondary efficacy variables (46%) and 23 patients in the Clm/Rib/Eth group (34%) had received prior antimycobacterial therapy; 12 patients in the included the following: duration of survival and determination of the susceptibility (MICs) of strains of M. avium isolated Clm/Clof group (18%) and nine patients in the Clm/Rib/Eth group (13%) had received rifabutin prophylaxis before entry from the initial blood culture and from persistently positive cultures or in the event of relapse. Relapse was defined as a into the study. The mean duration of study participation following inclusion was 186 days (Clm/Clof recipients, 176.5 days; positive blood culture at month 2. An intermediate analysis was planned for 6 months, at which time one-half of the total Clm/Rib/Eth recipients, 196 days). The median number of cfu of M. avium/mL of blood was 9 in the Clm/Clof group and 8 number of patients were enrolled in the study. Study progress was followed by an independent surveillance committee com-in the Clm/Rib/Eth group. posed of a clinician, bacteriologist, and methodologist.
Primary Efficacy Variables Statistical Analyses
There were no significant differences between the two treatment groups with respect to the principal efficacy variables Analyses were performed to compare baseline characteristics between the two treatment groups and to compare treatment (table 2) . At month 2, treatment was considered a success for 31 patients in the Clm/Clof group and 36 patients in the Clm/ outcome. Differences in categorical variables were evaluated by using the x 2 test with Yates' correction if necessary. Nor-Rib/Eth group, and at month 6, these numbers were nine and 14, respectively. At the end of the second month, treatment mally distributed continuous variables were assessed by using the Student's t test, and a Kaplan-Meier analysis with the failed for 28 Clm/Clof recipients (9 with fever, 9 with positive blood culture, 2 with fever and positive blood culture, 4 without logrank test was used to compare clinical variables (e.g., death and relapse). Comparisons were made on an intent-to-treat ba-blood culture performed, and 4 deaths) and 23 Clm/Rib/Eth / 9c37$$se16 08-20-97 09:17:19 cidas UC: CID recipients (4 with fever, 8 with positive blood culture, 2 with formed, and 19 deaths) and 29 Clm/Rib/Eth recipients (5 with fever, 4 with positive blood culture, 2 with fever and positive fever and positive blood culture, 1 with vision loss, 3 without blood culture performed, and 5 deaths). At the end of the sixth blood culture, 1 with vision loss, 2 without blood culture performed, and 15 deaths). There was an identical distribution in month, treatment failed for 34 Clm/Clof recipients (1 with fever, 4 with positive blood culture, 5 with fever and positive both groups in terms of the numbers of deaths, persistence of fever, and either positive blood cultures or blood cultures not blood culture, 3 with vision loss, 2 without blood culture per- performed. However, these primary determinants of success in global survival. Fluctuation of clarithromycin MICs was demonstrated for one patient: a susceptible strain was isolated did not take into account the relapses of mycobacterial infection that appeared between month 2 and month 6, as described at week 24, whereas resistant strains were isolated at weeks 20 and 36, respectively, strongly suggesting a polyclonal infection below.
with susceptible and resistant strains. The genomic fingerprinting of all strains from all patients is under study and will Secondary Efficacy Variables clarify the actual incidence of polyclonal, new, and/or recurrent infections. Bacteriologic failures. MICs were determined for 107 of 124 strains of M. avium isolated from culture specimens ob-Survival. Analysis of global survival, as estimated by the Kaplan-Meier method, revealed no statistically significant dif-tained on day 0. None of these strains showed resistance to clarithromycin (i.e., MICs were all õ4 mg/mL). All strains, ferences between treatment groups. There was a tendency, however, for the survival curves to split beyond 24 weeks of whatever the time of isolation, were susceptible to rifabutin, ethambutol, and clofazimine. However, two strains isolated treatment in favor of the combination of Clm/Rib/Eth (figure 2) . from specimens obtained on day 0 were resistant to rifabutin (MIC, ú8 mg/mL). One of these strains was isolated from a By 30 June 1995, there were a total of 52 deaths, 34 of which had occurred before the end of the sixth month of the patient who received rifabutin chemoprophylaxis before study entry; further isolates recovered from this patient were also study. Median survival following inclusion into the study was 34 weeks for Clm/Clof recipients and 52 weeks for Clm/Rib/ resistant to rifabutin (figure 1). At the end of the second month of treatment, blood cultures remained positive for 11 patients Eth recipients. Survival was not associated with baseline bacterial load or CD4 cell count, nor was it associated with the (six in the Clm/Clof group [isolates from two of these patients had acquired resistance to clarithromycin] and five in the Clm/ emergence of a resistant strain or relapse.
Concomitant events.
During the course of the study, there Rib/Eth group).
Between the end of the second and sixth months of treatment, were no significant differences between treatment groups with respect to the occurrence of concomitant opportunistic infec-relapse occurred in 28 patients (22 in the Clm/Clof group and six in the Clm/Rib/Eth group; P õ .001, between treatment tions or malignancies. In the Clm/Clof group and the Clm/Rib/ Eth group, respectively, the numbers of patients with concomi-groups) (table 3) . However, these patients did not necessarily have a positive blood culture at month 2 or 6. The emergence tant events were as follows: cytomegalovirus infection (21 and 19) , toxoplasmosis (3 and 6), pneumocystosis (1 and 0), cryp-of resistance to clarithromycin (MICs, ú128 mg/mL) was observed in 21 strains isolated from patients in the Clm/Clof tosporidiosis (1 and 7), septicemia (4 and 3), pneumonia (2 and 3), Kaposi's sarcoma (4 and 4), and non-Hodgkin's group but in only two strains isolated from patients in the Clm/ Rib/Eth group. The emergence of clarithromycin resistance was lymphoma (4 and 5). Adverse events and laboratory abnormalities. Overall, the not associated with prior antimycobacterial therapy. Because of significant emergence of clarithromycin resistance in isolates incidence of at least one adverse event was similar among the two treatment groups (42%, the Clm/Clof group; 49%, the Clm/ from the Clm/Clof group, the surveillance committee recommended stopping the study, despite no statistical difference Rib/Eth group). Initial therapy was discontinued because of adverse events in 9% of patients in the Clm/Clof group and 18% of patients in the Clm/Rib/Eth group. The primary reasons for discontinuation of therapy for Clm/Clof recipients and Clm/ Rib/Eth recipients were gastrointestinal events (nausea, vomiting, abdominal pain, and diarrhea; 4 and 5 patients, respectively) and hepatic toxic effects (jaundice and elevation of transaminase or alkaline phosphatase levels; 1 and 2 patients, respectively). Uveitis was observed in five Clm/Rib/Eth recipients (7%), but none of these cases resulted in serious visual sequelae. Of these five patients, one discontinued combination therapy, and four received a lower dosage of therapy (table 4) .
Discussion

Figure 1. Relapses in two groups of HIV-infected patients with
Clarithromycin is currently the most active macrolide against disseminated bacteremia due to Mycobacterium avium who received M. avium. In a randomized study of clarithromycin (2 g/d) [5] The optimal dosage of clarithromycin for curative treatment In a prospective study involving 43 HIV-positive patients [14] , ethambutol appeared to be active in vivo against has been determined to be between 1 and 2 g/d [7] . However, whereas eradication of M. avium can be achieved in most pa-M. avium. Rifabutin has been investigated in a number of open studies and as part of combination regimens in two placebo-tients during the first 2 months of treatment with clarithromycin, this agent does not prevent the emergence of resistant controlled, randomized studies [15, 16] .
In view of these results, current recommendations for the mutant strains beyond the second month; the risk of emergence of resistant strains has been reported to vary from 21% to 25% treatment of disseminated M. avium infection suggest a primary at a dosage of 2 g/d [7, 12] . The results of investigations involving clofazimine in vitro and in animal models are difficult to interpret because of the lipophilia of the molecule and its (1 vs. 1, respectively) . However, the median survival was better in the two-drug therapy group than one or more antibacterial agents [9] . Although these recommendations are largely followed in practice, no prospective studies in the three-drug therapy group (ú12 months vs. 6 months, respectively; P õ .014). There was no benefit to the addition have yet demonstrated the superiority of any particular combination regimen over another in terms of bacteriologic success, of clofazimine to the combination of antimicrobial agents. While bearing in mind these encouraging results, it is also tolerability, or prolongation of survival [17] . However, a recent study [18] confirmed the findings of Chaisson et al. [7] on important to acknowledge some of the limitations of our study. For example, there were no controls for bias (the study was not survival; it reported that most deaths occurred in patients treated with 2,000 mg of clarithromycin rather than 1,000 mg. blinded); however, the objective nature of the primary efficacy criteria countered this limitation and allowed for a reasonable Therefore, the recommendation now seems to be daily treatment with a 1,000-mg dose of clarithromycin.
comparison between the two treatment groups. The study was not designed to ascertain the relative usefulness of ethambutol In our study, the combination of Clm/Clof failed to eradicate M. avium in 11 of 59 evaluable patients at the end of the and rifabutin in the triple-drug regimen. A prospective trial presently under way in the United States (studying clarithro-second month of treatment, despite the use of higher dosages during the first 2 months. Moreover, among those patients mycin and ethambutol with or without rifabutin) should provide some insight into this issue. Despite the fact that a greater in whom initial bacteriologic eradication had been achieved, relapse occurred in 22 between the second and sixth months number of patients in the Clm/Rib/Eth group discontinued therapy because of adverse events, the tolerability of this combina-of treatment, and the emergence of strains highly resistant to clarithromycin was noted for 21 of these patients. Thus, our tion was still considered acceptable. The incidence of uveitis was moderate: 7% associated with a rifabutin dosage of 450 results disagree with those of Saint Marc and Touraine [13] who reported good clinical and bacteriologic efficacy with mg/d for patients weighing ú50 kg. This rate is markedly lower than the 39% incidence reported previously with rifabutin the combination Clm/Clof.
The combination of Clm/Rib/Eth proved to be as effective at a dosage of 600 mg/d [22] . as Clm/Clof but seemed to prevent the emergence of resistance to clarithromycin in this study. Similar to the results Conclusion observed for the Clm/Clof group, bacteriologic eradication by the end of the second month of treatment was not achieved
In the present study, the combination Clm/Rib/Eth was associated with clinical abatement of symptoms of M. avium infec-for 10 of 59 evaluable patients treated with Clm/Rib/Eth. However, in contrast to the Clm/Clof group, relapse between tion, prolonged mycobacterial eradication with a low risk of emergence of strains resistant to macrolides, and a tendency the end of the second and sixth months of treatment occurred in only six Clm/Rib/Eth recipients, and the emergence of toward prolonged survival for most patients. In contrast, the combination of Clm/Clof was associated with a high number resistant mutants was noted for only two of these patients. The favorable results observed in the present study with the of relapses of mycobacterial infection that, in most of these patients, were due to the emergence of resistant strains of Clm/Rib/Eth regimen are in agreement with those of a recent Canadian study [19] that compared this same combination M. avium. with a four-drug combination consisting of ciprofloxacin, ethambutol, rifampin, and clofazimine.
ANRS Curavium Trial 033 Group Members
Our findings agree with preliminary results from a randomized study [20] comparing clarithromycin/ethambutol/clofazi-In addition to the authors, the following principal clinical investigators (institutions [all of which are located in France]) mine with Clm/Clof that showed that three-drug therapy was more effective than two-drug therapy against relapses (5% vs. participated in this study. Dr. Blanc, Dr. Allegre, Dr. Chardon, and Dr. Bellon (CHG, Aix en Provence); Dr. Bru, Dr. Gaillat, 22%, respectively; P õ .003). The median delay before the emergence of resistance to clarithromycin was 7 months vs. 
